Atai Beckley NV
ATAI
Company Profile
Business description
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
Contact
Prof. J.H. Bavincklaan
Amstelveen1183 AT
NLDT: +31 207932536
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
54
Stocks News & Analysis
stocks
Undervalued ASX share searches for cost savings
Cost savings from recent acquisition underpin our earnings growth forecasts.
stocks
Chart of the Week: Where we see opportunities after year end market sell-off
The latest insights from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.50 | 43.90 | -0.49% |
| CAC 40 | 8,085.76 | 63.07 | 0.79% |
| DAX 40 | 24,294.61 | 164.47 | 0.68% |
| Dow JONES (US) | 48,703.09 | 645.34 | 1.34% |
| FTSE 100 | 9,703.16 | 47.63 | 0.49% |
| HKSE | 25,530.51 | 10.27 | -0.04% |
| NASDAQ | 23,518.87 | 135.29 | -0.57% |
| Nikkei 225 | 50,148.82 | 453.98 | -0.90% |
| NZX 50 Index | 13,395.87 | 24.81 | 0.19% |
| S&P 500 | 6,887.50 | 0.82 | 0.01% |
| S&P/ASX 200 | 8,592.00 | 39.50 | -0.46% |
| SSE Composite Index | 3,873.32 | 27.18 | -0.70% |